Ghaziabad Online

Dilated Cardiomyopathy (DCM) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Dilated Cardiomyopathy (DCM) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

May 20
03:46 2021
Dilated Cardiomyopathy (DCM) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Dilated Cardiomyopathy (DCM) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Dilated Cardiomyopathy (DCM), historical and forecasted epidemiology as well as the Dilated Cardiomyopathy (DCM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dilated Cardiomyopathy (DCM) is the most common type of non-ischemic heart muscle disease, occurring mostly in adults. It affects the lower chamber of the ventricle and the upper chamber of the atria of the heart. Normally, the disease starts in the left ventricle and the heart muscle begins to dilate which means that it stretches and becomes thinner. As a result, the inside of the chamber enlarges. The problem often spreads to the right ventricle and then to the atria. As the heart chambers dilate, the heart muscle does not contract normally and cannot pump blood very well. As the heart becomes weaker which in some situations leads to heart failure.

Currently, there is no approved therapy for the treatment of DCM, however, off-label therapies like beta-blockers, angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme inhibitors (ACEi), aldosterone antagonists, and diuretics are available to help control symptoms and prevent complications.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-dcm-market-insights

The Dilated Cardiomyopathy (DCM) market report also covers emerging drugs, current treatment practices, Dilated Cardiomyopathy (DCM) market share of the individual therapies, current and forecasted Dilated Cardiomyopathy (DCM) Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Dilated Cardiomyopathy (DCM) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Dilated Cardiomyopathy (DCM) Market

Dilated Cardiomyopathy (DCM) Market Key Facts

  • According to the research study of Hershberger, Hedges, & Morales (2013), DCM is more common than HCM and is found in more than 1 of 2,500 individuals. As per this study, the authors assumed that the ratio of idiopathic DCM to HCM was 2:1. Based on current and more rigorously validated estimates of the prevalence of HCM (1 in 500 individuals), the prevalence of idiopathic DCM is likely to be 1 in 250 individuals.

  • According to Mathew et al. (2017), in 50% of cases, the etiology of the disease remains unknown and is termed ‘Idiopathic DCM’. It is recognized that between 20% and 35% of idiopathic cases, some might be an inherited gene defects.

  • According to DelveInsight estimate, the total prevalent population of Dilated Cardiomyopathy in the 7MM was 2,523,808 in 2020.

  • The highest number of prevalent cases of Dilated cardiomyopathy were recorded in the United States. 

  • Among the European 5 countries, Germany had the highest diagnosed cases of Dilated cardiomyopathy with 81,214 cases in 2020, followed by France, Italy, and the United Kingdom. On the other hand, Spain had the lowest diagnosed cases of Dilated cardiomyopathy in 2020.

  • In 2020, Japan accounts for 89,421 and 38,323 of male and female cases respectively of Dilated Cardiomyopathy.

Key Benefits of Dilated Cardiomyopathy (DCM) Market Report

  • Dilated Cardiomyopathy (DCM) market report provides an in-depth analysis of Dilated Cardiomyopathy (DCM) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Dilated Cardiomyopathy (DCM) market report will help in developing business strategies by understanding the Dilated Cardiomyopathy (DCM) Market trends & developments, key players, and future market competition that will shape and drive the Dilated Cardiomyopathy (DCM) market in the upcoming years.

  • The Dilated Cardiomyopathy (DCM) market report covers Dilated Cardiomyopathy (DCM) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Dilated Cardiomyopathy (DCM) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Dilated Cardiomyopathy (DCM) Market

Dilated Cardiomyopathy (DCM) market is expected to increase during the forecast period owing to the increasing prevalence rate of heart disease, increasing healthcare spending, and emerging treatment options.

The Dilated Cardiomyopathy (DCM) market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Dilated Cardiomyopathy (DCM) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Dilated Cardiomyopathy (DCM) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Dilated Cardiomyopathy (DCM) Epidemiology

The Dilated Cardiomyopathy (DCM) epidemiology section covers insights about the historical and current Dilated Cardiomyopathy (DCM) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Dilated Cardiomyopathy (DCM) Epidemiology Segmentation –

  • Total Prevalent Population 

  • Total Diagnosed Population  

  • Familial and non-familial cases of Dilated Cardiomyopathy

  • Total Treated Cases of Dilated Cardiomyopathy

Dilated Cardiomyopathy (DCM) Drugs Uptake and Key Market Players

The Dilated Cardiomyopathy (DCM) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dilated Cardiomyopathy (DCM) market or expected to get launched in the market during the study period. The analysis covers Dilated Cardiomyopathy (DCM) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamic of the Dilated Cardiomyopathy (DCM) market is anticipated to change in the coming years owing to the rise in healthcare spending across the world. At present some of the key players worldwide are involved in developing drugs for Dilated Cardiomyopathy (DCM).

Dilated Cardiomyopathy (DCM) Companies:
Vericel
Pfizer
MyoKardia Inc.
Berlin Cures
Capricor Therapeutics
Cumberland Pharmaceuticals
And many others

Dilated Cardiomyopathy (DCM) Therapies covered in the report include:
BC 007
Ifetroban
CAP-1002
Ixmyelocel-T
PF-07265803/ARRY-371797
MYK-491
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Dilated Cardiomyopathy (DCM) Competitive Intelligence Analysis

4. Dilated Cardiomyopathy (DCM) Market Overview at a Glance

5. Dilated Cardiomyopathy (DCM) Disease Background and Overview

6. Dilated Cardiomyopathy (DCM) Patient Journey

7. Dilated Cardiomyopathy (DCM) Epidemiology and Patient Population

8. Dilated Cardiomyopathy (DCM) Treatment Algorithm, Current Treatment, and Medical Practices

9. Dilated Cardiomyopathy (DCM) Unmet Needs

10. Key Endpoints of Dilated Cardiomyopathy (DCM) Treatment

11. Dilated Cardiomyopathy (DCM) Marketed Products

12. Dilated Cardiomyopathy (DCM) Emerging Therapies

13. Dilated Cardiomyopathy (DCM) Seven Major Market Analysis

14. Attribute Analysis

15. Dilated Cardiomyopathy (DCM) Market Outlook (7 major markets)

16. Dilated Cardiomyopathy (DCM) Access and Reimbursement Overview

17. KOL Views on the Dilated Cardiomyopathy (DCM) Market.

18. Dilated Cardiomyopathy (DCM) Market Drivers

19. Dilated Cardiomyopathy (DCM) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-dcm-market-insights

Latest Reports By DelveInsight
Dilated Cardiomyopathy Pipeline Insights
Dilated Cardiomyopathy Pipeline
Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Dilated Cardiomyopathy (DCM) market.

US Healthcare Market Outlook
DelveInsight’s, “US Healthcare Outlook Report, 2020,” report provides comprehensive insights about healthcare scenarios, regulatory policies, and reimbursement landscape in the US. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of the US.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share